These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27766364)

  • 1. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.
    Kizhedath A; Wilkinson S; Glassey J
    Arch Toxicol; 2017 Apr; 91(4):1595-1612. PubMed ID: 27766364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Development of Therapeutic Monoclonal Antibodies.
    Mould DR; Meibohm B
    BioDrugs; 2016 Aug; 30(4):275-93. PubMed ID: 27342605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies.
    Brennan FR; Kiessling A
    Toxicol In Vitro; 2017 Dec; 45(Pt 3):296-308. PubMed ID: 28263892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical Safety and Toxicology.
    Stark C; Steger-Hartmann T
    Handb Exp Pharmacol; 2016; 232():261-83. PubMed ID: 26489827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.
    Sewell F; Chapman K; Couch J; Dempster M; Heidel S; Loberg L; Maier C; Maclachlan TK; Todd M; van der Laan JW
    MAbs; 2017 Jul; 9(5):742-755. PubMed ID: 28475417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.
    Brennan FR; Baumann A; Blaich G; de Haan L; Fagg R; Kiessling A; Kronenberg S; Locher M; Milton M; Tibbitts J; Ulrich P; Weir L
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):265-75. PubMed ID: 26219199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Drug Conjugates: Preclinical Considerations.
    Bornstein GG
    AAPS J; 2015 May; 17(3):525-34. PubMed ID: 25724883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicology Strategies for Drug Discovery: Present and Future.
    Blomme EA; Will Y
    Chem Res Toxicol; 2016 Apr; 29(4):473-504. PubMed ID: 26588328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P; Lasters I
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Models for Human and Animal Hepatotoxicity with a Global Application Scope.
    Mulliner D; Schmidt F; Stolte M; Spirkl HP; Czich A; Amberg A
    Chem Res Toxicol; 2016 May; 29(5):757-67. PubMed ID: 26914516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational toxicology: Its essential role in reducing drug attrition.
    Naven RT; Louise-May S
    Hum Exp Toxicol; 2015 Dec; 34(12):1304-9. PubMed ID: 26614820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of biological drugs: what are toxicology studies in primates telling us?
    Baldrick P
    Regul Toxicol Pharmacol; 2011 Mar; 59(2):227-36. PubMed ID: 20937341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.